Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Salarius Pharmaceuticals ( (SLRX) ) is now available.
In transactions from July 10, 2025 through July 30, 2025, Salarius Pharmaceuticals issued and sold 5.5 million shares of its common stock, generating approximately $3.8 million in gross proceeds. This transaction was conducted under a Securities Purchase Agreement with C/M Capital Master Fund, LP, and was exempt from registration under the Securities Act of 1933, indicating strategic financial maneuvering to bolster the company’s capital.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Average Trading Volume: 3,013,366
Technical Sentiment Signal: Sell
Current Market Cap: $2.13M
See more data about SLRX stock on TipRanks’ Stock Analysis page.